TABLE 1

Patient Demographics and Clinical Characteristics

CharacteristicHER2+ (n = 11)HER2– (n = 7)
Median age (y)59 y (age range, 35–75 y)61 y (age range, 40–71 y)
Hormone receptor and HER2 status of recurrence
 ER and PR receptors
  ER- and/or PR-positive63
  ER-negative and PR-negative54
 HER2
  IHC1+4
  IHC2+33
  IHC3+8
Prior HER2-directed therapy
 Trastuzumab for metastasis8 (79 d–36 mo)
 None37
Sites of metastatic disease measured for SUVmax
 Bone2412
 Lymph nodes2310
 Liver60
 Lung63
 Other*23
 Breast/chest wall55
Tumor volume (cm3)
 Mean5.812.2
 SE0.92.7
  • * Pulmonary effusion (HER2+) or body wall outside breast region.

  • Breast or chest wall adjacent to breast.

  • Volume within isocontour of 18F-FDG tumor image approximately matching boundary of CT correlate.

  • HER2 = human epidermal growth factor receptor 2; ER= estrogen receptor; PR= progesterone receptor; IHC = immunohistochemistry; SE = standard error.